Home
  • E-mailHrvoje.Miletic@uib.no
  • Phone+47 968 47 286
  • Visitor Address
    Jonas Lies vei 91
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2022). TGF-β promotes microtube formation in glioblastoma through thrombospondin 1. Neuro-Oncology. 541-553.
  • Show author(s) (2022). Refining the Role of Pyruvate Dehydrogenase Kinases in Glioblastoma Development. Cancers. 1-21.
  • Show author(s) (2022). Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells. Viruses.
  • Show author(s) (2022). Musculoskeletal Chronic Graft versus Host Disease-A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature. Current Oncology. 8415-8430.
  • Show author(s) (2022). Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis. EMBO Molecular Medicine. 1-20.
  • Show author(s) (2021). TGF-β promotes microtube formation in glioblastoma through thrombospondin 1. Neuro-Oncology. 541-553.
  • Show author(s) (2021). Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry. Nature Communications.
  • Show author(s) (2021). Genetic alterations associated with malignant transformation of sporadic vestibular schwannoma. Acta Neurochirurgica. 1-10.
  • Show author(s) (2021). Comparing tumor cell invasion and myeloid cell composition in compatible primary and relapsing glioblastoma. Cancers. 1-17.
  • Show author(s) (2020). Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. Immunity,Inflammation and Disease. 342-359.
  • Show author(s) (2020). Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathologica. 1-31.
  • Show author(s) (2020). Letter regarding "Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas". Neuro-Oncology. 1882-1883.
  • Show author(s) (2020). GADL1 is a multifunctional decarboxylase with tissue-specific roles in β-alanine and carnosine production. Science Advances. 1-19.
  • Show author(s) (2019). Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma. EMBO Molecular Medicine.
  • Show author(s) (2019). Therapeutic effect of cabazitaxel and blood-brain barrier opening in a patient-derived glioblastoma model. Nanotheranostics. 103-112.
  • Show author(s) (2019). Targeting APLN/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma. Cancer Research. 2298-2313.
  • Show author(s) (2019). Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. Cancers. 1-25.
  • Show author(s) (2019). Platelet‐derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients. Glia. 1-10.
  • Show author(s) (2019). PMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1. Oncogene. 1-15.
  • Show author(s) (2019). Mitochondrial DNA depletion in sporadic inclusion body myositis. Neuromuscular Disorders. 242-246.
  • Show author(s) (2019). Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma. Neuro-Oncology. 890-900.
  • Show author(s) (2019). Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-kappa B Signaling. Clinical Cancer Research. 6868-6881.
  • Show author(s) (2019). Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling. Brain. 512-530.
  • Show author(s) (2019). Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood-brain barrier. Molecular Cancer Therapeutics. 2171-2181.
  • Show author(s) (2019). Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 532-538.
  • Show author(s) (2019). Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes. OncoTarget. 3641-3653.
  • Show author(s) (2019). Deciphering the complex role of thrombospondin-1 in glioblastoma development. Nature Communications. 1-15.
  • Show author(s) (2019). Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013: Unexplainable regional differences in survival. Pediatric Blood & Cancer. 1-12.
  • Show author(s) (2019). Astrocytes enhance glioblastoma growth. Glia. 1-12.
  • Show author(s) (2018). Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. iScience.
  • Show author(s) (2018). Glioma through the looking GLASS: Molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology. 873-884.
  • Show author(s) (2017). Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts. BMC Cancer. 1-13.
  • Show author(s) (2017). The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. Journal of Experimental & Clinical Cancer Research. 1-15.
  • Show author(s) (2017). The angiogenic switch leads to a metabolic shift in human glioblastoma. Neuro-Oncology. 383-393.
  • Show author(s) (2017). Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy. OncoTarget. 12145-12157.
  • Show author(s) (2017). PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications. 1-14.
  • Show author(s) (2017). No evidence of ischemia in stroke-like lesions of mitochondrial POLG encephalopathy. Mitochondrion (Amsterdam. Print). 10-15.
  • Show author(s) (2017). Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathologica. 409-425.
  • Show author(s) (2017). Genetic landscape of sporadic vestibular schwannoma. Journal of Neurosurgery. 911-922.
  • Show author(s) (2017). EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro-Oncology. 743-752.
  • Show author(s) (2017). Cellular heterogeneity contributes to subtype-specific expression of ZEB1 in human glioblastoma. PLOS ONE. 1-15.
  • Show author(s) (2017). Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7. Experimental Cell Research. 64-73.
  • Show author(s) (2016). Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats. Journal of Neuro-Oncology.
  • Show author(s) (2016). Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells. OncoTarget.
  • Show author(s) (2016). Novel SLC19A3 promoter deletion and allelic silencing in biotin-thiamine-responsive basal ganglia encephalopathy. PLOS ONE.
  • Show author(s) (2016). Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. OncoTarget. 31955-31971.
  • Show author(s) (2016). Lentiviral HSV-Tk.007-mediated suicide gene therapy is not toxic for normal brain cells. Journal of Gene Medicine. 234-243.
  • Show author(s) (2016). EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. Neuro-Oncology. 1644-1655.
  • Show author(s) (2016). Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature Communications. 11 pages.
  • Show author(s) (2015). Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival. Neuro-Oncology. 223-242.
  • Show author(s) (2015). Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nature Cell Biology. 1556-1568.
  • Show author(s) (2015). Engraftment of human glioblastoma cells in immunocompetent rats through acquired immunosuppression. PLOS ONE.
  • Show author(s) (2015). Brain tumour cells interconnect to a functional and resistant network. Nature. 93-98.
  • Show author(s) (2015). Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathologica. 115-131.
  • Show author(s) (2014). Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Research. 3567-3578.
  • Show author(s) (2014). Molecular pathogenesis of polymerase gamma-related neurodegeneration. Annals of Neurology. 66-81.
  • Show author(s) (2013). Tumor versus stromal cells in culture-survival of the fittest? PLOS ONE. 12 pages.
  • Show author(s) (2013). Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. Brain. 2393-2404.
  • Show author(s) (2013). Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF. Radiology and Oncology. 330-337.
  • Show author(s) (2013). EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathologica. 683-698.
  • Show author(s) (2013). A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. PLOS ONE. e59773.
  • Show author(s) (2012). Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. 12 pages.
  • Show author(s) (2012). Focal myositis - A neurogenic phenomenon? Neuromuscular Disorders. 350-354.
  • Show author(s) (2012). Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour. European Journal of Endocrinology (EJE). 941-949.
  • Show author(s) (2012). Cellular host responses to gliomas. PLOS ONE. 12 pages.
  • Show author(s) (2012). Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI. Journal of Nuclear Medicine. 1135-1145.
  • Show author(s) (2011). Visualization of CD44 and CD133 in Normal Pancreas and Pancreatic Ductal Adenocarcinomas: Non-overlapping Membrane Expression in Cell Populations Positive for Both Markers. Journal of Histochemistry and Cytochemistry. 441-455.
  • Show author(s) (2011). Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma. PLOS ONE. 14 pages.
  • Show author(s) (2011). NUMB does not impair growth and differentiation status of experimental gliomas. Experimental Cell Research. 2864-2873.
  • Show author(s) (2011). Differential Activity of NADPH-Producing Dehydrogenases Renders Rodents Unsuitable Models to Study IDH1(R132) Mutation Effects in Human Glioblastoma. Journal of Histochemistry and Cytochemistry. 489-503.
  • Show author(s) (2011). Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. 3749-3754.
  • Show author(s) (2011). A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathology and Applied Neurobiology. 189-205.
  • Show author(s) (2010). Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research. 3356-3367.
  • Show author(s) (2010). Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment. Gene Therapy. 202-216.
  • Show author(s) (2009). iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Molecular & Cellular Proteomics. 2595-2612.
  • Show author(s) (2009). Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLOS ONE.
  • Show author(s) (2009). Methyl-L-C-11-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma. Journal of Nuclear Medicine. 1962-1968.
  • Show author(s) (2009). Developmental Potential of the Murine Embryonic Stem Cells Transplanted into the Healthy Rat Brain - Novel Insights into Tumorigenesis. Cellular Physiology and Biochemistry. 87-94.
  • Show author(s) (2009). A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer.
  • Show author(s) (2008). Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clinical Cancer Research. 1571-1580.
  • Show author(s) (2008). Multimodal imaging of neural progenitor cell fate in rodents. Molecular Imaging. 77-91.
  • Show author(s) (2007). Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clinical Cancer Research. 6761-6768.
Masters thesis
  • Show author(s) (2020). Studies on the Molecular Mechanisms of the Bystander Effect in HSV-TK mediated Suicide Gene Therapy for Glioblastoma Treatment.
  • Show author(s) (2019). Use of Gap Junction Enhanching Drugs to Increase the Bystander Effect of Sucide Gene Therapy for Glioblastoma Treatment.
  • Show author(s) (2018). The role of TGF-ß in tumour microtube formation and its effect on metabolism and mitochondrial dynamics in glioblastoma.
  • Show author(s) (2018). Role of Caveolin-1 in Hypoxia and Proneural to Mesenchymal Transition of Glioblastoma.
  • Show author(s) (2017). Screening of tumor suppressor microRNAs to boost the killing efficacy of suicide gene therapy for brain cancer treatment.
  • Show author(s) (2012). Toxicity and tropism of oncolytic VSV vectors in glioblastoma gene therapy.
  • Show author(s) (2009). Notch Pathway and Neural Stem Cell Markers are Regulated by the Epidermal Growth Factor Receptor in Glioblastoma Multiforme (GBM).
Letter to the editor
  • Show author(s) (2019). Fetal cerebral malakoplakia associated with recurrent facial erysipelas of the mother. Clinical Neuropathology.
  • Show author(s) (2017). Morvan syndrome with Caspr2 antibodies. Clinical and autopsy report. Journal of the Neurological Sciences. 453-455.
Doctoral dissertation
  • Show author(s) (2015). EGFR amplified glioblastoma cells: a challenge in research and therapy.
Academic chapter/article/Conference paper
  • Show author(s) (2019). Cancer Suicide Gene Therapy with TK.007. 16 pages.
Abstract
  • Show author(s) (2013). Mast cell upregulation in inclusion body myositis: a role for neurogenic inflammation? Neuropathology and Applied Neurobiology. 26-26.
  • Show author(s) (2013). GLIOBLASTOMA ADAPTATION TO ANTI-VASCULAR THERAPY INVOLVES AN UP-REGULATION OF GLYCOLYSIS WHERE LACTATE DEHYDROGENASE (LDH) REPRESENTS A POTENTIAL THERAPEUTIC TARGET. Neuro-Oncology. 7-7.
  • Show author(s) (2013). EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Neuro-Oncology. 6-6.
  • Show author(s) (2013). DISTINCT FUNCTIONAL ROLES OF WILD-TYPE EGFR AND ITS MUTANT EGFRvIII IN GLIOBLASTOMA DEVELOPMENT. Neuro-Oncology. 6-6.
  • Show author(s) (2013). ACTIVATION OF THE PROTOTYPICAL SFK c-Src PROMOTES ANGIOGENESIS OF HUMAN GLIOBLASTOMA. Neuro-Oncology. 3-3.
  • Show author(s) (2012). Polymerase gamma (POLG) associated encephalopathy is characterised by neuronal mtDNA depletion and respiratory complex-I deficiency. European Journal of Neurology. 63-63.
  • Show author(s) (2012). LCMV-Pseudotyped VSV-Based Systems for Treatment of Malignant Glioma. Human Gene Therapy. A101-A101.
  • Show author(s) (2011). TUMOR-ASSOCIATED GLIAL CELLS PROMOTE GROWTH OF GBM XENOGRAFTS IN EGFP NOD/SCID MICE. Neuro-Oncology. 55-55.
  • Show author(s) (2010). Successful engraftment of glioblastoma biopsy spheroids in immunocompetent rats. European Journal of Cancer. 76-76.
  • Show author(s) (2010). NESTIN-EXPRESSING CELLS IN TUMOR ANGIOGENESIS. Neuro-Oncology. 6-6.
  • Show author(s) (2009). PHENOTYPIC MODULATION OF EXPERIMENTAL GLIOMAS: PROGRESSION FROM GLIOMATOSIS CEREBRI-LIKE LESIONS TO GLIOBLASTOMA. Neuro-Oncology. 897-897.
  • Show author(s) (2009). MOLECULAR VARIATIONS IN TUMOR-HOST INTERACTIONS BETWEEN INVASIVE AND ANGIOGENIC PHENOTYPE IN HIGH-GRADE GLIOMAS. Neuro-Oncology. 961-961.
  • Show author(s) (2009). Lentiviral Vectors Mediate Efficient Suicide Gene Therapy in an Invasive Xenograft Model of Human Glioblastoma. Molecular Therapy. S302-S302.
  • Show author(s) (2008). Human glioblastoma tissue engraftment in immunocompetent rodent hosts. Neuro-Oncology. 815-815.
  • Show author(s) (2008). Efficient suicide gene therapy with lentiviral pseudotyped vectors in an invasive xenograft model of human glioblastoma. Neuro-Oncology. 797-798.
  • Show author(s) (2008). DEVELOPMENT OF A NEW BRAIN METASTASES MODEL IN IMMUNODEFICIENT ANIMALS. Neuro-Oncology. 854-854.
Poster
  • Show author(s) (2019). Blood brain barrier opening and Therapeutic Effect of Free and Nanoencapsulated Cabazitaxel in an Invasive Patient-Derived Glioblastoma Model.
  • Show author(s) (2014). Novel MYH7-mutations in Norwegian patients with distal myopathy.
Academic literature review
  • Show author(s) (2022). Tumor-associated macrophages in gliomas—basic insights and treatment opportunities. Cancers. 1-25.
  • Show author(s) (2020). Suicide gene therapy for the treatment of high-grade glioma: Past lessons, present trends, and future prospects. Neuro-Oncology Advances (NOA).
  • Show author(s) (2013). In vivo animal models for studying brain metastasis: value and limitations. Clinical and Experimental Metastasis. 695-710.
  • Show author(s) (2012). In vivo models of primary brain tumors: pitfalls and perspectives. Neuro-Oncology. 979-993.
  • Show author(s) (2009). Cancer stem cells and angiogenesis. Seminars in Cancer Biology. 279-284.
  • Show author(s) (2009). Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert opinion on therapeutic targets. 455-468.
Article in business/trade/industry journal
  • Show author(s) (2022). Hjernemetastasar – diagnostikk og behandling. Tidsskrift for Den norske legeforening. 1-7.

More information in national current research information system (CRIStin)